HKSE - Delayed Quote HKD

Alphamab Oncology (9966.HK)

7.340
+0.170
+(2.37%)
At close: May 9 at 4:08:05 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
640,083
640,083
218,774
166,845
146,021
Cost of Revenue
60,316
60,316
55,237
44,207
3,028
Gross Profit
579,767
579,767
163,537
122,638
142,993
Operating Expense
465,991
465,991
469,087
531,114
544,980
Operating Income
113,776
113,776
-305,550
-408,476
-401,987
Net Non Operating Interest Income Expense
39,331
39,331
61,863
19,660
14,625
Pretax Income
166,342
166,342
-210,593
-325,722
-412,417
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
166,342
166,342
-210,593
-325,722
-412,417
Diluted NI Available to Com Stockholders
166,342
166,342
-210,593
-325,722
-412,417
Basic EPS
-0.23
0.17
-0.22
-0.35
-0.44
Diluted EPS
-0.23
0.17
-0.22
-0.35
-0.44
Basic Average Shares
962,733
962,263
959,899
936,502
935,486
Diluted Average Shares
962,733
984,186
959,899
936,502
935,486
Total Expenses
526,307
526,307
524,324
575,321
548,008
Net Income from Continuing & Discontinued Operation
166,342
166,342
-210,593
-325,722
-412,417
Normalized Income
166,342
166,342
-210,593
-321,635
-423,412
Interest Income
49,255
49,255
74,042
33,866
27,807
Interest Expense
9,924
9,924
12,179
14,206
13,182
Net Interest Income
39,331
39,331
61,863
19,660
14,625
EBIT
176,266
176,266
-198,414
-311,516
-399,235
EBITDA
253,297
253,297
-129,296
-256,328
-358,133
Reconciled Cost of Revenue
60,316
60,316
55,237
44,207
3,028
Reconciled Depreciation
77,031
77,031
69,118
55,188
41,102
Net Income from Continuing Operation Net Minority Interest
166,342
166,342
-210,593
-325,722
-412,417
Total Unusual Items Excluding Goodwill
--
--
0
-4,087
10,995
Total Unusual Items
--
--
0
-4,087
10,995
Normalized EBITDA
253,297
253,297
-129,296
-252,241
-369,128
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 12/12/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

9995.HK RemeGen Co., Ltd.
37.450
-3.48%
 
9969.HK InnoCare Pharma Limited
9.650
+0.10%
 
1167.HK JACOBIO-B
3.960
+8.79%
 
2142.HK HBM Holdings Limited
8.990
+6.52%
 
688526.SS Wuhan Keqian Biology Co.,Ltd
16.40
-0.30%
 
1530.HK 3SBIO
12.080
+4.50%
 
288330.KQ Bridge Biotherapeutics, Inc.
804.00
-7.90%
 
3681.HK SinoMab BioScience Limited
1.300
+0.78%
 
2256.HK Abbisko Cayman Limited
7.830
+1.69%
 
1541.HK IMMUNEONCO-B
6.440
+0.78%